Abstract: The disclosed technology relates to chemical entities for the detection of wounds, e.g., chronic wounds or infected wounds, including compositions, substrates, kits, dressing materials, and articles, and systems containing such compounds. The disclosed technology further relates to methods of using these compositions, kits and systems in diagnostic assays, and in the diagnosis and/or detection of chronic or infected wounds based on enzymatic action on specific moieties and/or reaction sites. Additional disclosure relates to methods of characterizing wounds based on expression of a plurality of markers and using such information to treat, manage, and follow-up patients suffering from chronic or infected wounds.

Abstract: A method is provided for preparing a water-insoluble lignosulfonate polymer from a first solution containing lignosulfonate precursors, which involves a) separating the lignosulfonate precursors from the first solution and providing a second solution with at least 5 wt % of lignosulfonate precursors obtained from the first solution, wherein the separating comprises filtering out components with a predefined particle diameter and separating low-molecular weight components including salts and low-molecular organic compounds, b) adding a radical-forming enzyme and gas to the second solution, wherein the gas comprises oxygen, and c) polymerizing the lignosulfonate precursors of the resultant solution of b). Other related aspects are described and claimed.

Abstract: Disclosed is an abuse-deterrent pharmaceutical composition comprising a drug with an enzyme-reactive functional group, wherein the drug has an abuse potential, and an enzyme capable of reacting with the enzyme-reactive functional group (a drug-processing enzyme), wherein the drug with the enzyme-reactive functional group is contained in the pharmaceutical composition in a storage stable, enzyme-reactive state and under conditions wherein no enzymatic activity acts on the drug.

Abstract: Disclosed are pharmaceutical compositions comprising oxycodone and an oxycodone-processing enzyme, wherein oxycodone is contained in the pharmaceutical composition in a storage stable, enzyme-reactive state and under conditions wherein no enzymatic activity acts on oxycodone.

Abstract: Disclosed are pharmaceutical compositions comprising oxycodone and an oxycodone-processing enzyme, wherein oxycodone is contained in the pharmaceutical composition in a storage stable, enzyme-reactive state and under conditions wherein no enzymatic activity acts on oxycodone.

Abstract: The invention relates to a textile reinforcement material for reinforcing in particular rubber products, having at least one multi-fibre, which has aramid fibres having docking sites in the form of carboxyl groups arranged on the surface thereof for coupling in particular a rubber material, having an areal density of at least 0.2 nmol/mm2 and a tensile strength of the multi-fibre of at least 600 MPa.

Abstract: Disclosed are pharmaceutical compositions comprising a drug with a laccase-reactive functional group and a laccase (EC.10.3.2) and methods for manufacturing such compositions.

Abstract: Disclosed is an abuse-deterrent pharmaceutical composition comprising a drug with an enzyme-reactive functional group, wherein the drug has an abuse potential, and an enzyme capable of reacting with the enzyme-reactive functional group (a drug-processing enzyme), wherein the drug with the enzyme-reactive functional group is contained in the pharmaceutical composition in a storage stable, enzyme-reactive state and under conditions wherein no enzymatic activity acts on the drug.

Abstract: The invention relates to an arrangement, comprising a solid carrier and a matrix arranged on the solid carrier, said matrix comprising at least one enzymatically convertible or modifiable molecule and comprising at least one enzyme that can be released by the conversion or modification of the molecule, said enzyme being capable of converting at least one color-changing substrate located in the matrix and/or on the solid carrier.

Abstract: Described herein is a method for detecting a wound infection comprising the steps of: contacting a sample obtained from a wound with at least two substrates for at least two enzymes selected from the group consisting of lysozyme, elastase, cathepsin G and myeloperoxidase, and detecting a wound infection when a conversion of the at least two substrates with said at least two enzymes are determined.

Abstract: The invention relates to an arrangement, comprising a solid carrier and a matrix arranged on the solid carrier, said matrix comprising at least one enzymatically convertible or modifiable molecule and comprising at least one enzyme that can be released by the conversion or modification of the molecule, said enzyme being capable of converting at least one color-changing substrate located in the matrix and/or on the solid carrier.

Abstract: The present invention relates to agent compositions, in particular washing and cleaning agents, that contain a protease from a bacterial strain of the species Stenotrophomonas maltophilia, and to said proteases themselves. The invention further relates to cleaning methods in which said agents are used, and to uses of said agents. The invention further relates to the manufacture and use of these proteases themselves.

Abstract: A new process for enhancing the hydrophilicity of the surface of a polyolefin or polyolefin copolymer article is characterized in that the surface is treated with an enzyme selected from oxidoreductases, especially of the cytochrome P450 family or enzymes classified as EC 1.13 or EC 1.14. The process is especially useful for the treatment of polypropylene films, fibres, or fabrics, inter alia for use in sanitary articles, threads, yarns, fabrics, textiles, garments, technical or household articles, printed or dyed cover films or packaging films.